tbuckley/cabot-search huggingface dataset:
AB0427 Efficacy of hypnotic analgesia for the reduction of pain and negative emotional states in patients with rheumatoid arthritis of the “hospital civil de guadalajara “fray antonio alcalde”
Authors: F Bolaños-Chamorro, LA Hernandez-Palma, G Vazquez-Murillo, S Cerpa-Cruz, JF Muñoz-Valle, RM Meda-Lara
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Rheumatoid arthritis is a autoimmune and multisystemic disease. However, the negative emotions of anxiety and depression are the ones that have been most addressed, and there is a close relationship between pain associated with pain. Hypnosis is one of the best documented behavioral interventions in the management of acute and chronic pain in adults. <h3>Objectives</h3> To evaluate the efficacy of hypnotic analgesia for pain reduction and negative emotional states in patients with Rheumatoid Arthritis of the Guadalajara Civil Hospital Fray Antonio Alcalde <h3>Methods</h3> The method was developed through a quasi-experimental study, in which had two groups: a control group (CG) of 11 patients and an experimental group (EG) of 17, the women9s age group were developed between 18 and 65 years old diagnosed with arthritis. The medition of Pain was realized through an instrument called EVA, and for the case of the Anxiety and depression were through HAD, achieving the baseline of each one of the variables. The EG group attended three psychological sessions of Hypnosis, with intervals of one month each. In these sessions, the perception of pain with an EVA was measured at the beginning and at the end. After a month, the subsequent evaluation was performed, measuring the same initial variables, in order to make the comparison of the pre and pos. <h3>Results</h3> The U of MANN Whitney was applied and it was identified that in the pre-test measurement, there were no statistically significant differences in the variables. However, in the pos measurement, differences were found in the patient9s pain perception (z=-2.84, p&lt;0.05), anxiety (z=-2.36, p&lt;0.05) and The depression (z=-2.68, p&lt;0.05). In addition, a Wilcoxon test was developed to determine differences between the pre-test score and the pos-test score in the EVA of each session. Statistically significant differences were found in the first session (Z=-3.65, p=0.001), second session (Z=-3.67, p=0.001) and third session (Z=-3.56, p=0.001). <h3>Conclusions</h3> Hypnosis, as a behavioral technique, has shown efficacy in patients with chronic pain. In this research, a significant decrease in patients9 perception of pain has been demonstrated. <h3>References</h3> Chopra, A. (2013). The COPCORD world of musculoskeletal pain and arthritis. Rheumatology (United Kingdom), 52(11), 1925–1928. Matcham, F., Rayner, L., Steer, S., &amp; Hotopf, M. (2013). The prevalence of depression in rheumatoid arthritis: A systematic review and meta-analysis. Rheumatology (United Kingdom), 52(12), 2136–2148. <h3>Disclosure of Interest</h3> None declared
THU0763-HPR Addressing the elephant in the room: a possible new and effective way to increase patient adherence to medical advice
Authors: G Grønhaug, S Arnesen
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Lack of Patient adherence to medical advice (PAMA) are recognized as an era of interest for the last decades <sup>1</sup>. There have been several initiatives to improve PAMA such as patient centred care, shared decision-making, introduction of e-health and m-health. Although they are proven better than usual care, neither of these initiatives is proven successful. Outcome of medical interventions depends on complex psychological and sociocultural factors of which many are uncontrolled by health professionals. <h3>Objectives</h3> In the present study we assess beliefs about priorities in public health care, and adherence to medical advice to establish a novel approach to increase PAMA. <h3>Methods</h3> The Norwegian Citizen Panel (NCP) <sup>2</sup> is an experimental survey. Respondents are randomized to answer similar questions with slightly different wording. NCP is currently about 5000 respondents based on random selection performed by the Norwegian people register. The present study is based on responses to two question experiments from NCP adressing beliefs about priorities in public health care, and adherence to medical advice. The question on priorities in health care is divided in six groups (two control group, four experimental). The question on adherence is divided in three groups (one control group, two experimental). All questions are answered with a seven point Likert scale. <h3>Conclusions</h3> This study is the first to use experimental survey to assess PAMA. The result indicates that healthcare priorities form a base of trust between health care providers and patients. It further indicates that PAMA might increase if the healthcare provider refers to national expertise and patient organisations beliefs of a given treatment. This finding is supported by psychological theories of meaning-making<sup>3</sup>. Informing the patient about the views of the patient organisations and national expertise in the reasoning for a given treatment, may improve patient adherence to medical advices. <h3>References</h3> Costa E, Giardini A, Savin M, et al. Interventional tools to improve medication adherence: review of literature. Patient preference and adherence 2015;9:1303–14. doi: http://dx.doi.org/10.2147/PPA.S87551 [published Online First: 14.9.2015]. Ivarsflaten E. Norwegian citizen panel Wave 2, 2014. First NSD edition, Bergen 2014 ed. University of bergen, 2014. Lewis J. From culturalism to transculturalism. Iowa journal of cultural studies 2002;1:14–32. <h3>Acknowledgements</h3> Siv Mørkved for the suport and encouragement to do the study. <h3>Disclosure of Interest</h3> None declared
AB1101 Quality of life and work in patients with ankylosing spondylitis of working age
Authors: M Parvu, GM Muresan, AI Cozos, IA Biro, HV Popoviciu, S Szasz, S Voidazan
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> The assessment of the quality of life is a current research issue in patients with ankylosis spondylitis<sup>1,2</sup>. The tools for assessing the life quality, come to complete the other methods of investigation, which assess in a subjective manner the negative impact of the disease on daily activities. <h3>Objectives</h3> The purpose of this study is to define the functional ability, the disease activity, to investigate the correlation between work and quality of life, and the impact of the quality of life in patients with AS. <h3>Methods</h3> The study is an observational prospective study, which includes a total of 91 patients defined with AS in according to the modified New York criteria, from the Rheumatology Clinic of Targu-Mures. Data were obtained by questionnaires including several generic and disease related Quality of life tools. It includes specific tools: BASDAI (Bath Ankylosing Spondylitis Disease Activity Index); BASFI (Bath Ankylosing Spondylitis Functional Index); ASQOL (Ankylosing Spondylitis Quality of Life); and generic tools:SF-36 (Short-Form 36), Eq 5D (European-Quality of life 5 Dimensions), HAQ (Health Assessment Questionnaire and VAS (Visual Analogue Scale). <h3>Results</h3> Out of 91 patients, 82% were males, 18% were females; mean age (years) 50,27±11,05SD; age at disease onset (years)36,20±13,51SD; duration of disease (years) 14,22±9,69SD; retiring mean age (years) 44,54±7,65SD. The mean values for BASDAI=4,23±2,21SD; BASFI=4,88±2,61SD; EQ-5D=5,71±0,20SD; EQ-VAS=64,26±18,938D; HAQ=0,747±0,51SD; SF-physical summary=33,53±8,33SD; SF-emotional summary=47,57±10,03SD; ASQOL=6,94±2,68SD. We found a positive correlation between the disease onset and retiring age p&lt;0,0001, r=0,731a nd a negative significant correlation between BASFI and SFphysical summary (p&lt;0,0001, r=-0,798), ASQOL and SF-emotional summary, p&lt;0,0001, r=-0,595). <h3>Conclusions</h3> The results showed the invalidant potential of the AS, with major impact upon the quality of life. <h3>References</h3> Van der Heijde D, Landewe R. Assessment of disease activity, function and quality of life. In 1st edition Philadelfia:Mosby Elsevier;2006, 206–213. Dovard LC, McKenna SC, Meads MD et all. Translation and Validation of non English version of the ASQOL questionnaire. BioMed Central, Health and QOL outcomes, 2007, 5L7 doiL1.1186/1477–7525–5-7. <h3>Disclosure of Interest</h3> None declared
THU0632 Validation of internet-based reporting of patient reported outcomes within the swedish rheumatology quality register
Authors: OE Hofstedt, D Di Giuseppe, G-M Alenius, N Stattin, H Forsblad-d'Elia, L Ljung
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Previous studies have validated the use of clinic based touchscreens for registering patient reported outcome measures (PROMs) (1–3). The Swedish Rheumatology Quality (SRQ) register has implemented an internet-based method (PER (Patientens Egen Registrering, or Patients9 sElf Registration)) for collecting PROMs. <h3>Objectives</h3> The aim of this study was to investigate the feasibility of the internet-based method as well as the validity of reported outcomes and disease activity scores compared to the gold standard paper format. <h3>Methods</h3> We recruited patients (n=44, mean age =51.0, standard deviation =13.2 years, 69.6% women) included in SRQ with a diagnosis of rheumatoid arthritis, psoriatic arthritis, juvenile arthritis, spondyloarthritis or ankylosing spondylitis. Before a planned visit at the rheumatology clinic the patients registered Visual Analog Scales (VAS) for global health, pain and fatigue, both electronically by PER and on paper. Patients with axial disease also registered BASDAI and BASFI related variables (n=6). For patients with peripheral arthritis (n=38), DAS28 was calculated using both methods. The differences between the methods were compared by T-test and Intra-class correlation (ICC). Agreement was visualized using Bland-Altman plots for all VAS registrations. The patients also answered a questionnaire regarding the used device and preferred method. <h3>Results</h3> No differences between PER or paper based VAS scores were found for VAS Global, VAS Pain and VAS Fatigue (p=0.086, p=0.691 and p=0.197, respectively). ICC scores ranged from 0.930 to 0.971. Bland-Altman plots for VAS assessments showed good agreement and no proportional bias was detected (Fig 1). Mean difference for DAS28 was - 0.04 (p=0.177). Of the recruited patients, 78%, preferred the Internet based method. BASDAI and BASFI could not be evaluated due to a limited number of observations. <h3>Conclusions</h3> Internet based reporting of PROMs supply valid VAS data. DAS28 scores from the internet-based method presents an acceptable alternative to the traditional paper formats. <h3>References</h3> Greenwood MC, et al. Rheumatology (Oxford). 2006. Schefte DB, et al., Rheumatology (Oxford). 2010. Cunha-Miranda L, et al Rheumatol Int. 2015. <h3>Disclosure of Interest</h3> None declared
Prognostic Value of Risk Factors, Calcium Score, Coronary CTA, Myocardial Perfusion Imaging, and Invasive Coronary Angiography in Kidney Transplantation Candidates
Authors: Simon Winther, My Svensson, Hanne Skou Jørgensen, Laust Dupont Rasmussen, Niels Ramsing Holm, Lars Christian Gormsen, Kirsten Bouchelouche, Hans Erik Bøtker, Per Ivarsen, Morten Bøttcher
Journal: JACC. Cardiovascular imaging (2017)
AB0597 Low-dose rituximab as induction therapy for japanese patients with anca-associated vasculitis
Authors: Y Takakuwa, H Hanaoka, T Kiyokawa, K Ishimori, H Iida, H Nagafuchi, T Okazaki, S Ozaki
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Four times of once-weekly doses of 375 mg/m<sup>2</sup> rituximab (RTX) are frequently used as remission induction therapy for ANCA-associated vasculitis (AAV). Since this regimen has been basically generated from experience of B-cell non-Hodgkins9 lymphoma in the Europe and North America, appropriate dose and interval for patients with AAV in other population have been poorly investigated. Here we comprehensively analyzed the efficacy and tolerability of high or low dose regimen of RTX in Japanese patients with AAV. <h3>Objectives</h3> We investigated the efficacy and safety issue of low dose RTX for Japanese patients with AAV. <h3>Methods</h3> We retrospectively examined AAV patients who met the 2012 Chapel Hill classification from 2006 to 2016. We divided them into 2 groups, those treated with high-dose (HD) and low-dose (LD) RTX. HD RTX was the original regimen and LD RTX consisted of twice of one-weekly dose of 375 mg/m<sup>2</sup>. We evaluated cumulative complete remission (CR) rate and relapse-free rate for 1.5 years. CR was defined as BVAS=0 and relapse was defined as BVAS≧1. <h3>Results</h3> We evaluated 17 patients with HD and 11 patients with LD RTX. Higher percentage of elderly patients was observed in LD group (p&lt;0.01). No significant difference was found in BVAS (p=0.49) and VDI (p=0.15) before treatment. No significant difference was found in cumulative CR rate (p=0.90) (Fig. 1A), relapse-free rate (p=0.48) (Fig. 1B), B cells counts and serious adverse events. We found patients with nasal involvement and pulmonary nodule/cavity formation had higher relapse rate in LD group than those with HD group (p=0.05,and p=0.09 respectively). <h3>Conclusions</h3> LD regimen of RTX, especially in elderly patients, might be effective in remission induction therapy in AAV. <h3>References</h3> Ozaki S, et al. Mod Rheumatol 2012; 22: 394–404. <h3>Disclosure of Interest</h3> None declared
THU0447 Co-morbid gout is associated with increased cardiovascular risk factors in patients with type 2 diabetes, but not cardiovascular events or mortality
Authors: M Mian, SK Patel, B Wai, PM Srivastava, RRC Buchanan, LM Burrell
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Gout is an inflammatory arthropathy characterised by elevated serum uric acid levels. In Australia, gout has a prevalence of 1.7 - 4%.<sup>1</sup> This increased to ∼10% in community based Australian patients with type 2 diabetes, although elevated serum uric acid did not predict cardiovascular (CV) or all-cause mortality.<sup>2</sup> To date, the long-term outcomes of patients with diabetes and comorbid gout being followed up in the hospital out-patient setting have not been studied. <h3>Objectives</h3> To compare cardiovascular risk factors and long-term outcomes and mortality in patients with type 2 diabetes according to the presence or absence of gout. <h3>Methods</h3> 1,405 patients with type 2 diabetes were prospectively recruited from the outpatient setting at Austin Hospital. Baseline cardiovascular risk factors and comorbidities were identified. Patients were classified as having gout if they gave a history of gout or were taking medication for the treatment of gout. For statistical analysis, patients with diabetes (Group 1) were compared to those with diabetes and gout (Group 2). Cardiovascular events and long-term CV mortality were assessed over a 10 year period. <h3>Results</h3> There were 1,329 patients with diabetes (Group 1; 95%) and 76 with diabetes and gout (Group 2; 5%). Patients with gout were older (68±11 vs. 64±12y, p=0.004), more likely to be male (80% vs. 59%, p&lt;0.0001), with higher triglyceride levels (2.6 vs 1.9 mmol/L, p=0.002), lower HDL (1.05 vs. 1.24 mmol/L, p&lt;0.0001), higher BMI (33 vs. 31, p=0.026), and were more likely to have nephropathy (55% (n=35) vs. 26% (n=311), p&lt;0.0001) with increased albumin creatinine ratio (3.4 vs 1.8 g/mmol, p=0.002). Despite the worse cardiovascular risk profile in those with gout and diabetes, cardiovascular events and all-cause mortality were not significantly different between the groups (Group 1, 27% (n=333) vs. 35% (n=23) in Group 2, p=0.201). <h3>Conclusions</h3> Although patients with comorbid gout and type 2 diabetes have a worse cardiovascular risk factor profile compared to those with diabetes alone, this was not associated with increased cardiovascular morbidity or all-cause mortality. These results suggest that elevated uric acid and gout are markers rather than determinants of CV mortality. <h3>References</h3> Robinson PC, Taylor WJ, Merriman TR. Systemic review of the prevalence of gout and hyperuricaemia in Australia. Internal Med J 2012; 42(9):997–1007. Ong G, Davis WA, Davis TME. Serum uric acid does not predict cardiovascular or all-cause mortality in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2010; 53: 1288–129. <h3>Disclosure of Interest</h3> None declared
AB0477 Vitamin d status, systemic lupus erythematosus activity and endothelial dysfunction
Authors: A Caraba, V Crisan
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease, in which cardiovascular complications due to premature and accelerated atherosclerosis represent a serious problem. Endothelial dysfunction is the first step in the atherosclerosis development. Low levels of vitamin D have a high prevalence in lupus patients, correlating with high prevalence of cardiovascular diseases in these patients. <h3>Objectives</h3> The aim of this study was represented by the assessment of endothelial dysfunction in patients with active systemic lupus erythematosus, and correlations of this with SLE activity and vitamin D status. <h3>Methods</h3> The study was performed on a group of 35 female patients with active systemic lupus erythematosus. In all the patients were assessed: SLE activity using SLEDAI (SLE Disease Activity Index), vitamin D status and endothelial dysfunction by means of flow-mediated dilation (FMD). Data were presented as mean ± standard deviation. The statistically analysis was performed using Pearson9s test, p&lt;0.05 was considered statistically significant. <h3>Results</h3> The mean age of the studied patients was 33.68±8.55 years, and the average duration of SLE was 8.91±5.29 years. The assessed parameters had the values: SLEDAI 9.02±4.51, vitamin D 12.79±2.45 μg/l (4 patients had vitamin D deficiency, and 31 patients had vitamin D insufficiency), and FMD 9.26±2.34%. There were significant correlations between vitamin D levels and FMD (r =0.4517, p=0.003), and between vitamin D levels and SLEDAI (r = -0.6297, p=0.00025). <h3>Conclusions</h3> Low values of vitamin D levels were present in all the studied patients, correlating with the systemic lupus erythematosus activity, and endothelial dysfunction. <h3>References</h3> Reynolds JA, Bruce IN. Vitamin D in systemic lupus erythematosus: potential beyond bone health. Int J Clin Rheumatol 2009; 4(3): 297–309. Emam FE, Abd El-Wahab TM, Mohammed MS, et al. Assessment of serum vitamin D level in patients with systemic lupus erythematosus. Egypt Rheumatol Rehabil 2014; 41:71–78. <h3>Disclosure of Interest</h3> None declared
FRI0041 In vivo monitoring of anti-folate therapy in arthritic rats using [18f]fluoro-peg-folate and pet
Authors: DMSH Chandrupatla, CJ van der Laken, R Vos, M Verlaan, R van Kooij, AD Windhorst, Q Chen, PS Low, AA Lammertsma, G Jansen, CFM Molthoff
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Macrophages play a key role in the pathophysiology of rheumatoid arthritis (RA). The folate receptor β (FR-β) is expressed on these macrophages [1] and [<sup>18</sup>F]fluoro-PEG-folate positron emission tomography ([<sup>18</sup>F]fluoro-PEG-folate PET) can be used to visualize arthritis <i>in vivo</i> [2]. In addition, [<sup>18</sup>F]fluoro-PEG-folate PET could be a highly interesting tool for therapeutic monitoring of MTX therapy, the corner stone for RA therapy. <h3>Objectives</h3> To study the potential of [<sup>18</sup>F]fluoro-PEG-folate PET for monitoring response to MTX in a rat model of RA. <h3>Methods</h3> Arthritic rats [3] (n=3–6 per group) received interventions with either MTX [i.p., 1mg/kg; 2 times (group A) or 4 times (group B)] or PBS (control group)] with a time interval of 3–4 days. Healthy rats didn9t receive any arthritic induction or MTX therapy. [<sup>18</sup>F]fluoro-PEG-folate PET-CT were acquired for one hour after tracer injection [2]. Scans were analysed using the region of interest method and standardized uptake values (SUVs) were determined (50–60 min time frame). Sixty minutes after the PET scan, <i>ex-vivo</i> tissue distribution was performed and the amount of radioactivity measured in a gamma counter (expressed as percentage of the injected dose/gram tissue (%ID/g)) [2]. For histopathology (Haematoxylin-Eosin (HE) and immunohistochemistry with macrophage specific antibodies ED1 (∼CD68) and ED2 (∼CD163) were applied. Synovial macrophages were counted in predefined areas of the knees [3]. <h3>Results</h3> PET scans clearly visualized significantly lower SUVs (1.5-fold, p&lt;0.01) in arthritic knees of both MTX-treated groups, approximating the levels observed in healthy rats. Corroborating [<sup>18</sup>F]fluoro-PEG-folate PET, <i>ex vivo</i> tissue distribution [<sup>18</sup>F]fluoro-PEG-folate demonstrating a 2- and 4-fold decrease (group A and B, respectively) in tracer uptake in arthritic knees after MTX therapy (0.12 and 0.06 for groups A and B, and 0.22%ID/g for controls, respectively) (Figure). This reduction in uptake of [<sup>18</sup>F]fluoro-PEG-folate in arthritic knees was also associated with a significant decrease in ED1 and ED2 positive synovial macrophages in arthritic knees (∼4 fold) for both treated groups compared with control rats knees (p&lt;0.01). <h3>Conclusions</h3> This study in arthritic rats underscores the potential and usefulness of [<sup>18</sup>F]fluoro-PEG-folate PET as tool to monitor of MTX therapy and potentially other anti-folate treatments of RA. <h3>References</h3> Van der Heijden et al, Arthr &amp; Rheum (2009). Gent et al, Arthr Res Ther (2013). Chandrupatla et al, BioMed Res Int (2015). <h3>Disclosure of Interest</h3> None declared
Medical Sickness, Annuity, and Life Assurance Society: Tenth Report of the Committee to the Members for the Year ending June 30th, 1893
Authors: E. Hart, F. Addiscott
Journal: BMJ (1893)

JOUNXAZ~~~~~~~~~in some inland town no one would lhave been on the look-out for his case.In other cases, especially of foreign immi- grants, the names alnd addresses received in Leeds were often quite wrong.The other point was tllat both Mr. Ernest Hart and Dr. Alfred Hill stated broadly that in cholera treatment was of no use.Neither meant that all treatment was useless in cholera, and the expressions used had been, perhaps, too general.If it was meant that drugs did not cut short an attack of cholera any more than they did an attack of measles and scarlet fever, that would be admitted by all; but if it were meant that a patient unnursed and untended, attacked by cholera, lhad exactly the same clhance of recovery as a person carefully treated at liome or in hospital, that was misleading.
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
Authors: Anna Maria Fink, Jasmin Bahlo, Sandra Robrecht, Othman Al-Sawaf, Ali Aldaoud, Holger Hebart, Kathleen Jentsch-Ullrich, Steffen Dörfel, Kirsten Fischer, Clemens-Martin Wendtner, Thomas Nösslinger, Paolo Ghia, Francesc Bosch, Arnon P Kater, Hartmut Döhner, Michael Kneba, Karl-Anton Kreuzer, Eugen Tausch, Stephan Stilgenbauer, Matthias Ritgen, Sebastian Böttcher, Barbara Eichhorst, Michael Hallek
Journal: The Lancet Haematology (2017)